Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Altiratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | MET known ✓ | P08581 | 5/20 | 1.00 |
| ▸ | NTRK1 known ✓ | P04629 | 2/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 1/20 | 1.00 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 1.00 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 9/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.56 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.56 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altiratinib SCHEMBL30128694 | 1.00 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| Altiratinib SCHEMBL30337737 | 1.00 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| Altiratinib SCHEMBL139906 | 1.00 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL142079 | 0.96 | KDR (0.93) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL145837 | 0.93 | KDR (0.87) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL138396 | 0.90 | MET (0.82) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL2592755 | 0.90 | KDR (0.81) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL141721 | 0.90 | MET (0.81) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL143823 | 0.88 | MET (0.78) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL143639 | 0.88 | MET (0.78) | KDRMETNTRK1TEKNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694930-A1 | COMBINATION THERAPIES INVOLVING GREM1 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-20250205375-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2024262769-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASES, COMPRISING ALTIRATINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | 주식회사 인스팜텍 | 2024-12-26 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024213066-A1 | COMBINATION THERAPIES INVOLVING GREM1 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2024-10-17 | — | — | WO | claimed |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-22 | — | — | US | claimed |
| EP-4103197-A1 | TREATMENT OF OTIC DISEASES AND CONDITIONS | Spiral Therapeutics Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-20220363742-A1 | TREATMENTS OF MENIERE'S DISEASE | SPIRAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | claimed |
| WO-2022231294-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING SKIN PIGMENTATION | 재단법인 아산사회복지재단 | 2022-11-03 | — | — | WO | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-4054579-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-14 | — | — | EP | claimed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | KDR 172/4885MET 310/4885NTRK1 1/4885 |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | BRAF, FNTA, FNTB | KDR 278/4885MET 20/4885NTRK1 266/4885 |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | KDR 1440/4885MET 593/4885NTRK1 1437/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | KDR 4387/4885MET 3060/4885NTRK1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.